In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1939
Publisher
MDPI AG
Online
2019-12-05
DOI
10.3390/cancers11121939
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic And Predictive Impact Of Ighv Mutational Status And Load In Chronic Lymphocytic Leukemia: Focus On Fcr And Br Treatments
- (2019) Andrea Visentin et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia
- (2019) Federica Frezzato et al. INTERNATIONAL JOURNAL OF CANCER
- The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
- (2019) Andrea Visentin et al. BRITISH JOURNAL OF CANCER
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death
- (2018) Elisa Mandato et al. CURRENT CANCER DRUG TARGETS
- Critical molecular pathways in CLL therapy
- (2018) Gerardo Ferrer et al. MOLECULAR MEDICINE
- The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
- (2018) Sara Canovas Nunes et al. Blood Cancer Journal
- Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL
- (2018) Mario Angelo Pagano et al. LEUKEMIA
- Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells
- (2017) Elena Tibaldi et al. HAEMATOLOGICA
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells
- (2017) Uri Rozovski et al. INTERNATIONAL JOURNAL OF CANCER
- Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
- (2017) K Kondo et al. LEUKEMIA
- Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex
- (2017) Uri Rozovski et al. MOLECULAR CANCER RESEARCH
- Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells
- (2017) Elena Tibaldi et al. HAEMATOLOGICA
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial
- (2017) Preetesh Jain et al. Lancet Haematology
- Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
- (2016) D. E. Spaner et al. HAEMATOLOGICA
- Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins
- (2016) Federica Frezzato et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia
- (2016) L Quotti Tubi et al. LEUKEMIA
- Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
- (2016) D. E. Spaner et al. HAEMATOLOGICA
- Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A
- (2015) F. Zonta et al. BLOOD
- Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia
- (2015) Andrea Visentin et al. Clinical Lymphoma Myeloma & Leukemia
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
- (2015) U. Rozovski et al. MOLECULAR CANCER RESEARCH
- Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
- (2015) Valentina Trimarco et al. Oncotarget
- Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways
- (2015) Irene Amigo-Jiménez et al. Oncotarget
- Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole
- (2014) Federica Frezzato et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia
- (2014) C. Gattazzo et al. HAEMATOLOGICA
- Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma
- (2014) R Brown et al. LEUKEMIA
- Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, Tyrp-STAT-3, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance
- (2014) Georgia Levidou et al. Biomed Research International
- Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA in Small lymphocytic lymphoma/Chronic lymphocytic leukemia (CLL)
- (2013) Uri Rozovski et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
- (2013) Jan A. Burger et al. SEMINARS IN CANCER BIOLOGY
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor
- (2011) M. S. Redell et al. BLOOD
- STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
- (2011) R. B. Corcoran et al. CANCER RESEARCH
- STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells
- (2010) I. Hazan-Halevy et al. BLOOD
- Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
- (2009) A. V. Kurtova et al. BLOOD
- Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients
- (2009) A K Samanta et al. ONCOGENE
- Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia
- (2008) L. Trentin et al. BLOOD
- Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
- (2008) Gordon Shore et al. CURRENT MOLECULAR MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More